Gemini Therapeutics CMO Samuel Barone to depart April 15, 2022; advisory role continues

Disc Medicine, Inc.

Dr. Samuel Barone will leave as Chief Medical Officer effective April 15, 2022.
He receives 9 months base salary severance, pro-rata 2022 target bonus, and 9 months COBRA.
Barone will stay on as advisor, continuing to vest in existing equity during the advisory period.
Retention Agreement terms from Oct 4, 2021 govern severance; general release required.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Samuel Barone

Chief Medical Officer

IRON · Disc Medicine, Inc.

Effective: 2022-04-15
Filed: April 5, 2022, 7:59 PM ET

Effective as of April 15, 2022 (the “Separation Date”), Samuel Barone, M.D. will depart as the Chief Medical Officer of Gemini Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Samuel Barone departed as Chief Medical Officer at Disc Medicine, Inc..

Action: depart
Role: Chief Medical Officer

Exact text from the filing

Effective as of April 15, 2022 (the “Separation Date”), Samuel Barone, M.D. will depart as the Chief Medical Officer of Gemini Therapeutics, Inc.

View on SEC.gov

Disc Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-095633

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.